150 related articles for article (PubMed ID: 10194357)
1. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.
Gopal YN; Jayaraju D; Kondapi AK
Biochemistry; 1999 Apr; 38(14):4382-8. PubMed ID: 10194357
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II is a cellular target for antiproliferative cobalt salicylaldoxime complex.
Jayaraju D; Gopal YN; Kondapi AK
Arch Biochem Biophys; 1999 Sep; 369(1):68-77. PubMed ID: 10462441
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
Vashisht Gopal YN; Konuru N; Kondapi AK
Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene.
Vashisht Gopal YN; Jayaraju D; Kondapi AK
Arch Biochem Biophys; 2000 Apr; 376(1):229-35. PubMed ID: 10729210
[TBL] [Abstract][Full Text] [Related]
5. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
[TBL] [Abstract][Full Text] [Related]
6. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
7. DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium(II) and rhodium(III) complexes.
Singh SK; Joshi S; Singh AR; Saxena JK; Pandey DS
Inorg Chem; 2007 Dec; 46(25):10869-76. PubMed ID: 18001110
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
Sai Krishna AD; Panda G; Kondapi AK
Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
Skladanowski A; Plisov SY; Konopa J; Larsen AK
Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
[TBL] [Abstract][Full Text] [Related]
11. Light-induced anticancer activity of [RuCl2(DMSO)4] complexes.
Brindell M; Kuliś E; Elmroth SK; Urbańska K; Stochel G
J Med Chem; 2005 Nov; 48(23):7298-304. PubMed ID: 16279789
[TBL] [Abstract][Full Text] [Related]
12. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity.
Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E
Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042
[TBL] [Abstract][Full Text] [Related]
13. Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B.
Mura P; Camalli M; Casini A; Gabbiani C; Messori L
J Inorg Biochem; 2010 Feb; 104(2):111-7. PubMed ID: 19939460
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structural characteristics, DNA binding properties and cytotoxicity studies of a series of Ru(III) complexes.
Tan C; Liu J; Chen L; Shi S; Ji L
J Inorg Biochem; 2008 Aug; 102(8):1644-53. PubMed ID: 18468690
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, GC selective DNA binding and topoisomerase II inhibition activities of ruthenium(II) polypyridyl complex containing 11-aminopteridino[6,7-f][1,10]phenanthrolin-13(12H)-one.
Gao F; Chao H; Zhou F; Chen X; Wei YF; Ji LN
J Inorg Biochem; 2008; 102(5-6):1050-9. PubMed ID: 18295337
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium.
Vashisht Gopal YN; Kondapi AK
J Biosci; 2001 Jun; 26(2):271-6. PubMed ID: 11426063
[TBL] [Abstract][Full Text] [Related]
17. Effect of charge transfer bands on the photo-induced DNA cleavage activity of [1-(2-thiazolylazo)-2-naphtholato]copper(II) complexes.
Dhar S; Nethaji M; Chakravarty AR
J Inorg Biochem; 2005 Mar; 99(3):805-12. PubMed ID: 15708802
[TBL] [Abstract][Full Text] [Related]
18. DNA as a possible target for antitumor ruthenium(III) complexes.
Gallori E; Vettori C; Alessio E; Vilchez FG; Vilaplana R; Orioli P; Casini A; Messori L
Arch Biochem Biophys; 2000 Apr; 376(1):156-62. PubMed ID: 10729201
[TBL] [Abstract][Full Text] [Related]
19. DNA conformational changes and cleavage by ruthenium(II) nitrofurylsemicarbazone complexes.
Otero L; Smircich P; Vieites M; Ciganda M; Severino PC; Terenzi H; Cerecetto H; Gambino D; Garat B
J Inorg Biochem; 2007 Jan; 101(1):74-9. PubMed ID: 17027974
[TBL] [Abstract][Full Text] [Related]
20. Effect of ancillary ligands on the topoisomerases II and transcription inhibition activity of polypyridyl ruthenium(II) complexes.
Chen X; Gao F; Zhou ZX; Yang WY; Guo LT; Ji LN
J Inorg Biochem; 2010 May; 104(5):576-82. PubMed ID: 20167375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
